Switch theme
Sign up to access all valuation multiples
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
2005
270
LTM Revenue $41.3M
LTM EBITDA -$338M
$730M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Syndax has a last 12-month revenue of $41.3M and a last 12-month EBITDA of -$338M.
In the most recent fiscal year, Syndax achieved revenue of $23.7M and an EBITDA of -$314M.
Syndax expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Syndax valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | $23.7M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$209M | -$314M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -1325% | XXX | XXX | XXX |
| Net Profit | -$149M | -$209M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -884% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Syndax's stock price is $11.
Syndax has current market cap of $967M, and EV of $730M.
See Syndax trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $730M | $967M | XXX | XXX | XXX | XXX | $-3.76 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Syndax has market cap of $967M and EV of $730M.
Syndax's trades at 17.7x LTM EV/Revenue multiple, and -2.2x LTM EBITDA.
Analysts estimate Syndax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Syndax and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $730M | XXX | XXX | XXX |
| EV/Revenue | 30.8x | XXX | XXX | XXX |
| EV/EBITDA | -2.3x | XXX | XXX | XXX |
| P/E | -3.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSyndax's NTM/LTM revenue growth is 191%
Syndax's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Syndax's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Syndax's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Syndax and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | Infinity% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1325% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 50% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1134% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 510% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1020% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1531% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Syndax acquired XXX companies to date.
Last acquisition by Syndax was XXXXXXXX, XXXXX XXXXX XXXXXX . Syndax acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Syndax founded? | Syndax was founded in 2005. |
| Where is Syndax headquartered? | Syndax is headquartered in United States of America. |
| How many employees does Syndax have? | As of today, Syndax has 270 employees. |
| Who is the CEO of Syndax? | Syndax's CEO is Mr. Michael A. Metzger. |
| Is Syndax publicy listed? | Yes, Syndax is a public company listed on NAS. |
| What is the stock symbol of Syndax? | Syndax trades under SNDX ticker. |
| When did Syndax go public? | Syndax went public in 2016. |
| Who are competitors of Syndax? | Similar companies to Syndax include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Syndax? | Syndax's current market cap is $967M |
| What is the current revenue of Syndax? | Syndax's last 12-month revenue is $41.3M. |
| What is the current EBITDA of Syndax? | Syndax's last 12-month EBITDA is -$338M. |
| What is the current EV/Revenue multiple of Syndax? | Current revenue multiple of Syndax is 17.7x. |
| What is the current EV/EBITDA multiple of Syndax? | Current EBITDA multiple of Syndax is -2.2x. |
| Is Syndax profitable? | Yes, Syndax is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
